Answer: C
The correct answer is C - Interventions that target contributing symptoms, such as sleep disturbance and chemotherapy induced peripheral neuropathy, can lead to improvements in cancer-related fatigue and quality of life.
Rationale Based on Evidence
While the provided evidence does not contain specific data from the OASIS-4 elizanetant study or URCC 19075 exercise trial mentioned in the question, I can analyze the answer choices based on the comprehensive guideline evidence about cancer-related fatigue management:
Why Option C is Correct
The most recent ASCO guideline 1 strongly recommends exercise (aerobic, resistance, or combination) to reduce the severity of fatigue during cancer treatment with moderate evidence quality. The 2024 guideline 1 specifically notes that exercise interventions demonstrated benefits for multiple contributing symptoms:
- Sleep disturbance: A meta-analysis showed moderate reduction in sleep disturbance with exercise interventions (SMD -0.47; 95% CI, -0.88 to -0.05) 1
- Quality of life improvements: Consistently demonstrated across multiple trials 1
- Symptom-directed approach: The guidelines emphasize that targeting contributing factors leads to meaningful fatigue reduction
Why Other Options are Incorrect
Option A (pharmacologic interventions alone): The guidelines clearly demonstrate that non-pharmacologic interventions, particularly exercise, are the primary evidence-based approach 1. Nine out of 13 trials comparing exercise to control conditions showed significant benefits 1. Pharmacologic interventions have limited evidence and are not recommended as first-line therapy.
Option B (only during active treatment): The evidence contradicts this. The 2010 Cochrane analysis 2 showed exercise was effective both during treatment (SMD -0.18) and after therapy (SMD -0.37), with actually larger effect sizes post-treatment. The 2024 guideline 1 confirms benefits across the cancer continuum.
Option D (no meaningful effects): This is directly contradicted by the evidence. The 2024 ASCO guideline 1 provides a strong recommendation for exercise based on moderate-quality evidence showing clinically meaningful improvements in fatigue. Meta-analyses demonstrate effect sizes of -0.42 for fatigue reduction 2, which is considered clinically significant.
Key Evidence Points
The guidelines consistently show that:
- Exercise interventions reduce cancer-related fatigue with effect sizes ranging from -0.23 to -0.42 2
- Multiple modalities work: aerobic, resistance, or combined approaches all demonstrate benefit 1
- Symptom improvement is multifaceted: benefits extend to sleep, quality of life, and physical function 3, 1
- Both supervised and unsupervised programs are effective 1
The evidence base strongly supports that interventions targeting contributing symptoms—whether through exercise addressing deconditioning and sleep disturbance, or other symptom-directed therapies—lead to meaningful improvements in cancer-related fatigue and quality of life, making Option C the most accurate reflection of current evidence.